NASH
MCID: NNL004
MIFTS: 55

Nonalcoholic Fatty Liver Disease (NASH)

Categories: Cancer diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Nonalcoholic Fatty Liver Disease

MalaCards integrated aliases for Nonalcoholic Fatty Liver Disease:

Name: Nonalcoholic Fatty Liver Disease 12 25 37 15
Non-Alcoholic Fatty Liver Disease 12 25 73
Nonalcoholic Steatohepatitis 25 73
Fatty Liver 25 73
Susceptibility to Nonalcoholic Fatty Liver Disease 6
Non-Alcoholic Steatohepatitis 25
Fatty Degeneration 73
Steatohepatitis 73
Steatosis 25
Nafld 25
Nash 25

Classifications:



External Ids:

Disease Ontology 12 DOID:0080208
KEGG 37 H01333

Summaries for Nonalcoholic Fatty Liver Disease

Genetics Home Reference : 25 Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat.

MalaCards based summary : Nonalcoholic Fatty Liver Disease, also known as non-alcoholic fatty liver disease, is related to hepatocellular carcinoma and psoriasis. An important gene associated with Nonalcoholic Fatty Liver Disease is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Non-alcoholic fatty liver disease (NAFLD) and Glycerolipid metabolism. The drugs Tocopherol and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and ovary.

Disease Ontology : 12 A fatty liver disease characterized by the storing of excess fat in liver cells which is is not caused by heavy alcohol use.

Wikipedia : 76 Non-alcoholic fatty liver disease (NAFLD) is a condition where excess fat builds up in the liver due to... more...

Related Diseases for Nonalcoholic Fatty Liver Disease

Diseases in the Nonalcoholic Fatty Liver Disease family:

Fatty Liver Disease, Nonalcoholic 1 Fatty Liver Disease, Nonalcoholic 2

Diseases related to Nonalcoholic Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 408)
# Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 31.0 MIR122 MIR130A MIR183 MIR200A MIR203A MIR26A1
2 psoriasis 30.7 MIR122 MIR200A MIR203A MIRLET7E
3 leukemia, acute lymphoblastic 30.2 MIR130A MIR203A MIR451A MIRLET7E
4 breast cancer 30.1 MIR10B MIR122 MIR200A MIR203A MIR34A MIR429
5 prostate cancer 29.9 MIR10B MIR183 MIR203A MIR34A MIRLET7D MSR1
6 lymphoma, hodgkin, classic 29.7 MIR140 MIR200A
7 muscular dystrophy, duchenne type 29.6 MIR130A MIR34A
8 lung cancer 29.3 MIR130A MIR140 MIR183 MIR200A MIR203A MIR26A1
9 fatty liver disease, nonalcoholic 2 12.3
10 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 12.2
11 fatty liver disease 12.2
12 lipoatrophy with diabetes, leukomelanodermic papules, liver steatosis, and hypertrophic cardiomyopathy 12.1
13 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.0
14 fatty liver disease, nonalcoholic 1 11.8
15 liver disease 11.6
16 lipodystrophy, familial partial, type 2 11.6
17 reye syndrome 11.5
18 congenital generalized lipodystrophy 11.3
19 visceral steatosis, congenital 11.2
20 corticosteroid-binding globulin deficiency 11.1
21 lipodystrophy, congenital generalized, type 2 11.1
22 lipodystrophy, congenital generalized, type 3 11.1
23 lipodystrophy, familial partial, type 6 11.1
24 nonalcoholic steatohepatitis 10.9
25 neutral lipid storage disease with myopathy 10.9
26 combined oxidative phosphorylation deficiency 16 10.9
27 morbid obesity and spermatogenic failure 10.9
28 mitochondrial dna depletion syndrome 4a 10.9
29 chylomicron retention disease 10.9
30 adrenomyodystrophy 10.9
31 lipodystrophy, congenital generalized, type 1 10.9
32 3-methylglutaconic aciduria, type v 10.9
33 hypermanganesemia with dystonia 1 10.9
34 lipodystrophy, congenital generalized, type 4 10.9
35 lipodystrophy, familial partial, type 5 10.9
36 muscular dystrophy, limb-girdle, autosomal recessive 18 10.9
37 interstitial lung and liver disease 10.9
38 combined oxidative phosphorylation deficiency 21 10.9
39 infantile liver failure syndrome 2 10.9
40 mitochondrial dna depletion syndrome 15 10.9
41 bile acid synthesis defect, congenital, 6 10.9
42 diabetes mellitus 10.8
43 hepatitis 10.7
44 diabetes mellitus, noninsulin-dependent 10.7
45 sleep apnea 10.5
46 hepatitis b 10.5
47 polycystic ovary syndrome 10.5
48 hepatitis c 10.5
49 hyperuricemia 10.5
50 helicobacter pylori infection 10.4

Graphical network of the top 20 diseases related to Nonalcoholic Fatty Liver Disease:



Diseases related to Nonalcoholic Fatty Liver Disease

Symptoms & Phenotypes for Nonalcoholic Fatty Liver Disease

Drugs & Therapeutics for Nonalcoholic Fatty Liver Disease

Drugs for Nonalcoholic Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 336)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
2
Amlodipine Approved Phase 4 88150-42-9 2162
3
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
4
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
5
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
6
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
7
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6
8
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
9
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
10
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
11
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
12
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
13
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
14
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
15
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 122320-73-4 77999
16
Insulin Detemir Approved Phase 4 169148-63-4 5311023
17
Insulin Aspart Approved Phase 4 116094-23-6 16132418
18
Gliclazide Approved Phase 4 21187-98-4 3475
19 tannic acid Approved Phase 4,Phase 3,Not Applicable
20
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
21
Rifampicin Approved Phase 4,Phase 1 13292-46-1 5458213 5381226
22
Empagliflozin Approved Phase 4,Not Applicable 864070-44-0
23
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
24
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
25
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 80621-81-4 6436173
26
Glimepiride Approved Phase 4 93479-97-1 3476
27 Dulaglutide Approved, Investigational Phase 4,Not Applicable 923950-08-7
28
Saxagliptin Approved Phase 4 361442-04-8 11243969
29
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-02-9 14985
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 59-30-3 6037
31
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3 65-23-6 1054
32
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-14-6 5280793
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
34
Methionine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 63-68-3 6137
35
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 5280795 6221
36
Ginseng Approved, Investigational, Nutraceutical Phase 4,Not Applicable 50647-08-0
37 Tocotrienol Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6829-55-6
38
2,4-thiazolidinedione Investigational Phase 4,Phase 2 2295-31-0
39
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
40 Tocotrienols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Tocopherols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Angiotensin-Converting Enzyme Inhibitors Phase 4
44
protease inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
45 Vasodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Antihypertensive Agents Phase 4,Phase 3,Phase 2
47 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 2
48 HIV Protease Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
49 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3,Phase 2
50 Angiotensinogen Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 695)
# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
3 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
4 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
5 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
6 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
7 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
8 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
9 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
10 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
11 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4 Exenatide
12 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
13 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
14 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
15 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
16 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
17 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
18 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
19 The Effects of PXR Activation on Hepatic Fat Content Completed NCT02329405 Phase 4 Rifampicin;Placebo
20 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
21 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
22 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients" (SETH2) Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
23 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
24 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
25 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
26 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
27 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
28 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
29 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
30 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Recruiting NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
31 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
32 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4 Metformin;Placebo
33 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Recruiting NCT02964715 Phase 4 Empagliflozin
34 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Recruiting NCT02984475 Phase 4 Metformin
35 Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease Active, not recruiting NCT03796975 Phase 4 Combination of Pioglitazone and Metformin Tablets;Metformin Hydrochloride Tablets
36 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease Active, not recruiting NCT03222206 Phase 4 Salsalate
37 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Enrolling by invitation NCT02210715 Phase 4 Isentress.
38 Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver Not yet recruiting NCT03646292 Phase 4 Pioglitazone;Empagliflozin;Combination of pioglitazone and empagliflozin
39 Silymarin in NAFLD Not yet recruiting NCT02973295 Phase 4 Silymarin
40 Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Not yet recruiting NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
41 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis Not yet recruiting NCT03198572 Phase 4 Placebo;Berberine
42 Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) Not yet recruiting NCT03648554 Phase 4 dulaglutide (TRULICITY®) 1.5 mg
43 High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes Not yet recruiting NCT03403556 Phase 4 Rosuvamibe;Monorova
44 Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) Terminated NCT00736385 Phase 4 Glucophage (Metformin);Placebo
45 Fatty Liver Study in Patients With Type II Diabetes Terminated NCT02365233 Phase 4 DPP4 inhibitor;Pioglitazone;Lantus insulin
46 Rifaximin in Fatty Liver Disease Terminated NCT01355575 Phase 4 Rifaximin
47 Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH Terminated NCT01406704 Phase 4 Rosiglitazone;alpha-lipoic acid;Rosiglitazone/alpha-lipoic acid
48 Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI Withdrawn NCT02263677 Phase 4 Sitagliptin
49 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle
50 Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Unknown status NCT00658164 Phase 3

Search NIH Clinical Center for Nonalcoholic Fatty Liver Disease

Genetic Tests for Nonalcoholic Fatty Liver Disease

Anatomical Context for Nonalcoholic Fatty Liver Disease

MalaCards organs/tissues related to Nonalcoholic Fatty Liver Disease:

41
Liver, Testes, Ovary, Endothelial, Heart, Kidney, Bone

Publications for Nonalcoholic Fatty Liver Disease

Articles related to Nonalcoholic Fatty Liver Disease:

(show top 50) (show all 2731)
# Title Authors Year
1
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. ( 30430605 )
2019
2
The Future of Nonalcoholic Fatty Liver Disease Treatment. ( 30466676 )
2019
3
Fatty liver disease: is it nonalcoholic fatty liver disease or obesity-associated fatty liver disease? ( 30507644 )
2019
4
Vitamin E alleviates non-alcoholic fatty liver disease in phosphatidylethanolamine N-methyltransferase deficient mice. ( 30300671 )
2019
5
Olive oil lessened fatty liver severity independent of cardiometabolic correction in patients with non-alcoholic fatty liver disease: A randomized clinical trial. ( 30170304 )
2019
6
Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. ( 30134384 )
2019
7
Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease. ( 30016770 )
2019
8
The Pattern of Elevated Liver Function Tests in Nonalcoholic Fatty Liver Disease Predicts Fibrosis Stage and Metabolic-Associated Comorbidities. ( 30016799 )
2019
9
Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. ( 29846945 )
2019
10
Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation. ( 29429367 )
2018
11
Simultaneous quantification of hepatic MRI-PDFF and R2* in a rabbit model with nonalcoholic fatty liver disease. ( 29934919 )
2018
12
Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. ( 29946793 )
2018
13
Nonalcoholic Fatty Liver Disease: Time to Take the Bull by the Horns. ( 29963461 )
2018
14
Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease. ( 29951367 )
2018
15
PNPLA3: A Determinant of Response to Low-Fructose Diet in Nonalcoholic Fatty Liver Disease. ( 29452087 )
2018
16
A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis. ( 29942422 )
2018
17
Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey. ( 29235054 )
2018
18
Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. ( 29438460 )
2018
19
Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study. ( 29434074 )
2018
20
Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. ( 29969922 )
2018
21
Correction: Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. ( 29944727 )
2018
22
Evaluation of nonalcoholic fatty liver disease using magnetic resonance in obese children and adolescents. ( 29438686 )
2018
23
Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. ( 29368124 )
2018
24
Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. ( 29931231 )
2018
25
Huperzine A attenuates nonalcoholic fatty liver disease by regulating hepatocyte senescence and apoptosis: an in vitro study. ( 29967757 )
2018
26
Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. ( 29404514 )
2018
27
Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. ( 29956688 )
2018
28
Associations of hyperuricemia and obesity with remission of nonalcoholic fatty liver disease among Chinese men: A retrospective cohort study. ( 29415050 )
2018
29
Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance. ( 29968484 )
2018
30
Relationship between diverticulosis and nonalcoholic fatty liver disease in elderly patients. ( 29432700 )
2018
31
A comprehensive bioinformatics analysis on multiple Gene Expression Omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. ( 29769552 )
2018
32
Association of Lipoprotein-Associated Phospholipase A2 with the Prevalence of Nonalcoholic Fatty Liver Disease: A Result from the APAC Study. ( 29973631 )
2018
33
Nonalcoholic Fatty Liver Disease in University Rugby Football Players. ( 29973915 )
2018
34
Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease. ( 29955036 )
2018
35
Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease. ( 29948305 )
2018
36
Sarcopenia and risk of nonalcoholic fatty liver disease: A meta-analysis. ( 29451179 )
2018
37
Developmental Origins of Nonalcoholic Fatty Liver Disease (NAFLD). ( 29956192 )
2018
38
Association between nonalcoholic fatty liver disease and colorectal Tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. ( 29935236 )
2018
39
Hepatopulmonary syndrome caused by hypothalamic obesity and nonalcoholic fatty liver disease after surgery for craniopharyngioma: a case report. ( 29609450 )
2018
40
Non-Invasive Diagnosis of Nonalcoholic Fatty Liver Disease. ( 29937542 )
2018
41
Nonalcoholic fatty liver disease with prolactin-secreting pituitary adenoma in an adolescent: A case report. ( 30335007 )
2018
42
Interatrial septal fat thickness and left atrial stiffness are mechanistic links between nonalcoholic fatty liver disease and incident atrial fibrillation. ( 30548700 )
2018
43
Non-alcoholic fatty liver disease in patients with autoimmune hepatitis. ( 30483564 )
2018
44
Association between Nonalcoholic Fatty Liver Disease and Carotid Artery Disease in a Community-Based Chinese Population: A Cross-Sectional Study. ( 30246712 )
2018
45
Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis. ( 29193593 )
2018
46
Non-alcoholic fatty liver disease and colorectal cancer survival. ( 30443695 )
2018
47
Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. ( 29627620 )
2018
48
Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. ( 29399276 )
2018
49
Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. ( 30551263 )
2018
50
Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus. ( 30460863 )
2018

Variations for Nonalcoholic Fatty Liver Disease

ClinVar genetic disease variations for Nonalcoholic Fatty Liver Disease:

6 (show top 50) (show all 92)
# Gene Variation Type Significance SNP ID Assembly Location
1 PNPLA3 NM_025225.2(PNPLA3): c.*71T> G single nucleotide variant Uncertain significance rs886057601 GRCh37 Chromosome 22, 44342333: 44342333
2 PNPLA3 NM_025225.2(PNPLA3): c.-112A> T single nucleotide variant Likely benign rs531789428 GRCh38 Chromosome 22, 43923800: 43923800
3 PNPLA3 NM_025225.2(PNPLA3): c.-112A> T single nucleotide variant Likely benign rs531789428 GRCh37 Chromosome 22, 44319680: 44319680
4 PNPLA3 NM_025225.2(PNPLA3): c.-111G> A single nucleotide variant Likely benign rs548897706 GRCh38 Chromosome 22, 43923801: 43923801
5 PNPLA3 NM_025225.2(PNPLA3): c.-111G> A single nucleotide variant Likely benign rs548897706 GRCh37 Chromosome 22, 44319681: 44319681
6 PNPLA3 NM_025225.2(PNPLA3): c.-44C> G single nucleotide variant Uncertain significance rs773713393 GRCh38 Chromosome 22, 43923868: 43923868
7 PNPLA3 NM_025225.2(PNPLA3): c.-44C> G single nucleotide variant Uncertain significance rs773713393 GRCh37 Chromosome 22, 44319748: 44319748
8 PNPLA3 NM_025225.2(PNPLA3): c.972C> T (p.Leu324=) single nucleotide variant Likely benign rs116679026 GRCh37 Chromosome 22, 44333145: 44333145
9 PNPLA3 NM_025225.2(PNPLA3): c.972C> T (p.Leu324=) single nucleotide variant Likely benign rs116679026 GRCh38 Chromosome 22, 43937265: 43937265
10 PNPLA3 NM_025225.2(PNPLA3): c.980-15A> C single nucleotide variant Likely benign rs144872932 GRCh37 Chromosome 22, 44335858: 44335858
11 PNPLA3 NM_025225.2(PNPLA3): c.980-15A> C single nucleotide variant Likely benign rs144872932 GRCh38 Chromosome 22, 43939978: 43939978
12 PNPLA3 NM_025225.2(PNPLA3): c.992A> G (p.Glu331Gly) single nucleotide variant Likely benign rs144233415 GRCh37 Chromosome 22, 44335885: 44335885
13 PNPLA3 NM_025225.2(PNPLA3): c.992A> G (p.Glu331Gly) single nucleotide variant Likely benign rs144233415 GRCh38 Chromosome 22, 43940005: 43940005
14 PNPLA3 NM_025225.2(PNPLA3): c.1209C> T (p.Pro403=) single nucleotide variant Uncertain significance rs184910573 GRCh37 Chromosome 22, 44340667: 44340667
15 PNPLA3 NM_025225.2(PNPLA3): c.1209C> T (p.Pro403=) single nucleotide variant Uncertain significance rs184910573 GRCh38 Chromosome 22, 43944787: 43944787
16 PNPLA3 NM_025225.2(PNPLA3): c.1340G> A (p.Arg447Gln) single nucleotide variant Uncertain significance rs147289545 GRCh37 Chromosome 22, 44342156: 44342156
17 PNPLA3 NM_025225.2(PNPLA3): c.1340G> A (p.Arg447Gln) single nucleotide variant Uncertain significance rs147289545 GRCh38 Chromosome 22, 43946276: 43946276
18 PNPLA3 NM_025225.2(PNPLA3): c.1358G> T (p.Ser453Ile) single nucleotide variant Likely benign rs6006460 GRCh37 Chromosome 22, 44342174: 44342174
19 PNPLA3 NM_025225.2(PNPLA3): c.1358G> T (p.Ser453Ile) single nucleotide variant Likely benign rs6006460 GRCh38 Chromosome 22, 43946294: 43946294
20 PNPLA3 NM_025225.2(PNPLA3): c.*19T> G single nucleotide variant Uncertain significance rs569255289 GRCh37 Chromosome 22, 44342281: 44342281
21 PNPLA3 NM_025225.2(PNPLA3): c.*19T> G single nucleotide variant Uncertain significance rs569255289 GRCh38 Chromosome 22, 43946401: 43946401
22 PNPLA3 NM_025225.2(PNPLA3): c.*71T> G single nucleotide variant Uncertain significance rs886057601 GRCh38 Chromosome 22, 43946453: 43946453
23 PNPLA3 NM_025225.2(PNPLA3): c.*691_*692dupAA duplication Likely benign rs397716964 GRCh37 Chromosome 22, 44342953: 44342954
24 PNPLA3 NM_025225.2(PNPLA3): c.*691_*692dupAA duplication Likely benign rs397716964 GRCh38 Chromosome 22, 43947073: 43947074
25 PNPLA3 NM_025225.2(PNPLA3): c.*889A> G single nucleotide variant Likely benign rs1810508 GRCh38 Chromosome 22, 43947271: 43947271
26 PNPLA3 NM_025225.2(PNPLA3): c.*889A> G single nucleotide variant Likely benign rs1810508 GRCh37 Chromosome 22, 44343151: 44343151
27 PNPLA3 NM_025225.2(PNPLA3): c.*988_*989dupAA duplication Likely benign rs397775086 GRCh38 Chromosome 22, 43947370: 43947371
28 PNPLA3 NM_025225.2(PNPLA3): c.*988_*989dupAA duplication Likely benign rs397775086 GRCh37 Chromosome 22, 44343250: 44343251
29 PNPLA3 NM_025225.2(PNPLA3): c.*1090A> G single nucleotide variant Likely benign rs9626058 GRCh38 Chromosome 22, 43947472: 43947472
30 PNPLA3 NM_025225.2(PNPLA3): c.*1090A> G single nucleotide variant Likely benign rs9626058 GRCh37 Chromosome 22, 44343352: 44343352
31 PNPLA3 NM_025225.2(PNPLA3): c.*987_*989dupAAA duplication Uncertain significance rs397775086 GRCh38 Chromosome 22, 43947369: 43947371
32 PNPLA3 NM_025225.2(PNPLA3): c.-168C> A single nucleotide variant Likely benign rs140746182 GRCh38 Chromosome 22, 43923744: 43923744
33 PNPLA3 NM_025225.2(PNPLA3): c.-168C> A single nucleotide variant Likely benign rs140746182 GRCh37 Chromosome 22, 44319624: 44319624
34 PNPLA3 NM_025225.2(PNPLA3): c.187+12G> A single nucleotide variant Likely benign rs116795637 GRCh38 Chromosome 22, 43924110: 43924110
35 PNPLA3 NM_025225.2(PNPLA3): c.187+12G> A single nucleotide variant Likely benign rs116795637 GRCh37 Chromosome 22, 44319990: 44319990
36 PNPLA3 NM_025225.2(PNPLA3): c.216T> C (p.Leu72=) single nucleotide variant Uncertain significance rs147412464 GRCh38 Chromosome 22, 43926963: 43926963
37 PNPLA3 NM_025225.2(PNPLA3): c.216T> C (p.Leu72=) single nucleotide variant Uncertain significance rs147412464 GRCh37 Chromosome 22, 44322843: 44322843
38 PNPLA3 NM_025225.2(PNPLA3): c.309G> A (p.Pro103=) single nucleotide variant Likely benign rs79118505 GRCh38 Chromosome 22, 43927056: 43927056
39 PNPLA3 NM_025225.2(PNPLA3): c.309G> A (p.Pro103=) single nucleotide variant Likely benign rs79118505 GRCh37 Chromosome 22, 44322936: 44322936
40 PNPLA3 NM_025225.2(PNPLA3): c.*987_*989dupAAA duplication Uncertain significance rs397775086 GRCh37 Chromosome 22, 44343249: 44343251
41 PNPLA3 NM_025225.2(PNPLA3): c.646A> C (p.Thr216Pro) single nucleotide variant Uncertain significance rs35726887 GRCh37 Chromosome 22, 44328917: 44328917
42 PNPLA3 NM_025225.2(PNPLA3): c.646A> C (p.Thr216Pro) single nucleotide variant Uncertain significance rs35726887 GRCh38 Chromosome 22, 43933037: 43933037
43 PNPLA3 NM_025225.2(PNPLA3): c.659A> G (p.Tyr220Cys) single nucleotide variant Uncertain significance rs143392071 GRCh37 Chromosome 22, 44328930: 44328930
44 PNPLA3 NM_025225.2(PNPLA3): c.659A> G (p.Tyr220Cys) single nucleotide variant Uncertain significance rs143392071 GRCh38 Chromosome 22, 43933050: 43933050
45 PNPLA3 NM_025225.2(PNPLA3): c.980-14A> C single nucleotide variant Uncertain significance rs781212740 GRCh37 Chromosome 22, 44335859: 44335859
46 PNPLA3 NM_025225.2(PNPLA3): c.980-14A> C single nucleotide variant Uncertain significance rs781212740 GRCh38 Chromosome 22, 43939979: 43939979
47 PNPLA3 NM_025225.2(PNPLA3): c.1112+14G> A single nucleotide variant Uncertain significance rs138736228 GRCh37 Chromosome 22, 44336019: 44336019
48 PNPLA3 NM_025225.2(PNPLA3): c.1112+14G> A single nucleotide variant Uncertain significance rs138736228 GRCh38 Chromosome 22, 43940139: 43940139
49 PNPLA3 NM_025225.2(PNPLA3): c.1300A> G (p.Lys434Glu) single nucleotide variant Likely benign rs2294918 GRCh37 Chromosome 22, 44342116: 44342116
50 PNPLA3 NM_025225.2(PNPLA3): c.1300A> G (p.Lys434Glu) single nucleotide variant Likely benign rs2294918 GRCh38 Chromosome 22, 43946236: 43946236

Cosmic variations for Nonalcoholic Fatty Liver Disease:

9 (show top 50) (show all 3307)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1626018 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 18
2 COSM1615665 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 18
3 COSM1602238 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 18
4 COSM6951673 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 18
5 COSM1616325 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 18
6 COSM3707827 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 18
7 COSM3707828 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 18
8 COSM1623051 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 18
9 COSM1612127 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 18
10 COSM1618451 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581L 4:145885684-145885684 18
11 COSM1611545 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 18
12 COSM1612685 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47V 19:52002156-52002156 18
13 COSM1612018 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 18
14 COSM1618219 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 18
15 COSM1624399 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 18
16 COSM1609798 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 18
17 COSM1605856 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 18
18 COSM1602404 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 18
19 COSM1607880 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221A 14:67807621-67807621 18
20 COSM3661787 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 18
21 COSM1270878 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 18
22 COSM1612900 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 18
23 COSM3663890 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 18
24 COSM6969923 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 18
25 COSM3717069 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 18
26 COSM6219678 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 18
27 COSM1613453 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 18
28 COSM3717124 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 18
29 COSM1608898 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 18
30 COSM3705381 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 18
31 COSM1601838 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 18
32 COSM1610770 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 18
33 COSM1601260 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 18
34 COSM1624206 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2136A>G p.T712T 8:80518852-80518852 18
35 COSM1624207 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2311A>G p.I771V 8:80519295-80519295 18
36 COSM1616586 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 18
37 COSM1624117 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1568A>G p.N523S 8:63187582-63187582 18
38 COSM1603361 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 18
39 COSM1617254 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167N 3:183722100-183722100 18
40 COSM3663693 XPO7 liver,NS,carcinoma,hepatocellular carcinoma c.806A>G p.Y269C 8:21977812-21977812 18
41 COSM1609152 XPO6 liver,NS,carcinoma,hepatocellular carcinoma c.882C>T p.G294G 16:28156289-28156289 18
42 COSM6957749 XPO1 liver,NS,carcinoma,hepatocellular carcinoma c.301+1G>C p.? 2:61522610-61522610 18
43 COSM1624082 XKR4 liver,NS,carcinoma,hepatocellular carcinoma c.1076A>G p.D359G 8:55523350-55523350 18
44 COSM1613650 XIRP2 liver,NS,carcinoma,hepatocellular carcinoma c.9350G>C p.R3117P 2:167250742-167250742 18
45 COSM3660541 XIRP1 liver,NS,carcinoma,hepatocellular carcinoma c.142C>A p.Q48K 3:39189304-39189304 18
46 COSM1625463 XIAP liver,NS,carcinoma,hepatocellular carcinoma c.493G>T p.A165S 23:123886155-123886155 18
47 COSM3663909 WWP1 liver,NS,carcinoma,hepatocellular carcinoma c.210-2A>G p.? 8:86381503-86381503 18
48 COSM1625309 WWC3 liver,NS,carcinoma,hepatocellular carcinoma c.1121C>A p.S374Y 23:10117180-10117180 18
49 COSM1621161 WTAP liver,NS,carcinoma,hepatocellular carcinoma c.283C>T p.Q95* 6:159748200-159748200 18
50 COSM6909096 WT1 liver,NS,carcinoma,hepatocellular carcinoma c.1019T>G p.L340* 11:32396283-32396283 18

Expression for Nonalcoholic Fatty Liver Disease

Search GEO for disease gene expression data for Nonalcoholic Fatty Liver Disease.

Pathways for Nonalcoholic Fatty Liver Disease

Pathways related to Nonalcoholic Fatty Liver Disease according to KEGG:

37
# Name Kegg Source Accession
1 Non-alcoholic fatty liver disease (NAFLD) hsa04932
2 Glycerolipid metabolism hsa00561

Pathways related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.8 MIR10B MIR122 MIR183 MIR200A MIR203A MIR26A1
2 10.96 MIR203A MIRLET7D
3 10.79 MIR200A MIR429
4 10.4 MIRLET7D MIRLET7E

GO Terms for Nonalcoholic Fatty Liver Disease

Cellular components related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 MIR10B MIR122 MIR130A MIR140 MIR183 MIR26A1
2 micro-ribonucleoprotein complex GO:0035068 9.44 MIR10B MIR122 MIR130A MIR140 MIR183 MIR200A

Biological processes related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.47 MIR10B MIR122 MIR130A MIR140 MIR183 MIR200A
2 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.32 MIR130A MIR26A1
3 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.26 MIR140 MIR34A
4 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.16 MIR26A1 MIR451A
5 negative regulation of vascular associated smooth muscle cell migration GO:1904753 8.96 MIR140 MIR34A

Molecular functions related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.32 MIR10B MIR130A MIR140 MIR200A MIR203A MIR26A1
2 RNA polymerase II complex binding GO:0000993 8.96 MIR140 MIR378A

Sources for Nonalcoholic Fatty Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....